Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOWL NASDAQ:NLTX NASDAQ:OGI NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOWLWerewolf Therapeutics$1.35+3.1%$1.17$0.60▼$4.18$58.79M0.62438,440 shs341,656 shsNLTXNeoleukin Therapeutics$21.47-3.5%$18.68$2.03▼$14.36$201.78M1.1150,104 shs142,891 shsOGIOrganigram Global$1.46+2.1%$1.36$0.85▼$2.08$191.53M1.36662,653 shs447,668 shsPROKProKidney$3.73+10.7%$1.22$0.46▼$7.13$986.39M1.263.54 million shs11.44 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOWLWerewolf Therapeutics+3.05%+26.17%+3.85%+46.90%-54.24%NLTXNeoleukin Therapeutics-3.55%+5.87%+8.65%+99.35%-53.07%OGIOrganigram Global+2.10%+1.39%+2.10%+36.45%-16.57%PROKProKidney+10.68%-14.06%+278.18%+371.61%+54.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOWLWerewolf Therapeutics3.7981 of 5 stars3.55.00.00.01.65.00.6NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global1.137 of 5 stars0.01.00.00.03.10.02.5PROKProKidney3.3625 of 5 stars3.24.00.00.03.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOWLWerewolf Therapeutics 3.00Buy$8.33517.28% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 0.00N/AN/AN/APROKProKidney 2.40Hold$6.2567.56% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, OGI, NLTX, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $9.006/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.005/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOWLWerewolf Therapeutics$1.14M53.00N/AN/A$1.65 per share0.82NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AOGIOrganigram Global$117.47M1.66N/AN/A$2.07 per share0.71PROKProKidney$80K13,647.14N/AN/A($3.41) per share-1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AOGIOrganigram Global-$33.39M$0.1014.60N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest HOWL, OGI, NLTX, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/AHOWLWerewolf Therapeutics-$0.50N/AN/AN/AN/AN/A8/12/2025Q3 2025OGIOrganigram Global-$0.01N/AN/AN/A$68.04 millionN/A8/8/2025Q2 2025PROKProKidney-$0.14N/AN/AN/AN/AN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOWLWerewolf Therapeutics0.468.098.09NLTXNeoleukin TherapeuticsN/A15.3315.33OGIOrganigram GlobalN/A3.421.90PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOWLWerewolf Therapeutics64.84%NLTXNeoleukin Therapeutics52.37%OGIOrganigram Global34.63%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipHOWLWerewolf Therapeutics23.60%NLTXNeoleukin Therapeutics1.58%OGIOrganigram Global0.09%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataOGIOrganigram Global860133.94 million133.82 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableHOWL, OGI, NLTX, and PROK HeadlinesRecent News About These CompaniesNew Strong Buy Stocks for July 17th2 hours ago | zacks.comProKidney gains pivotal therapy advancement step with FDA2 hours ago | journalnow.comJProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?July 16 at 1:01 PM | zacks.comProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst UpgradeJuly 16 at 2:18 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Up on Analyst UpgradeJuly 16 at 2:27 AM | americanbankingnews.comPromising clinical trial results give ProKidney share price major boostJuly 15 at 11:46 PM | journalnow.comJProKidney stock soars after FDA confirms accelerated approval pathwayJuly 15 at 11:46 PM | in.investing.comProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug TrialJuly 15 at 11:46 PM | marketwatch.comProKidney Shares Dip Following FDA Agreement on Rilparencel Approval StrategyJuly 15 at 11:46 PM | msn.comProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15 at 11:46 PM | finance.yahoo.comProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst UpgradeJuly 15 at 11:57 AM | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from BrokeragesJuly 15 at 11:53 AM | marketbeat.comProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and DiabetesJuly 15 at 7:46 AM | quiverquant.comQProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15 at 7:30 AM | globenewswire.comProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst UpgradeJuly 14 at 11:55 AM | marketbeat.comGuggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00July 14 at 10:54 AM | marketbeat.comPromising clincial trial results give ProKidney share price major boostJuly 14 at 10:31 AM | greensboro.comGProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?July 14 at 10:31 AM | msn.comProKidney's (PROK) "Buy" Rating Reiterated at CitigroupJuly 12, 2025 | americanbankingnews.comProKidney (NASDAQ:PROK) Sees Large Volume Increase Following Analyst UpgradeJuly 12, 2025 | americanbankingnews.comProKidney (PROK) Gets a Sell from Bank of America SecuritiesJuly 11, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractWhy Occidental's Price Dip Signals a Buying OpportunityBy Jeffrey Neal Johnson | July 3, 2025View Why Occidental's Price Dip Signals a Buying OpportunityHOWL, OGI, NLTX, and PROK Company DescriptionsWerewolf Therapeutics NASDAQ:HOWL$1.35 +0.04 (+3.05%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Neoleukin Therapeutics NASDAQ:NLTX$21.47 -0.79 (-3.55%) As of 07/15/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Organigram Global NASDAQ:OGI$1.46 +0.03 (+2.10%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.43 -0.03 (-2.05%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.ProKidney NASDAQ:PROK$3.73 +0.36 (+10.68%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$3.86 +0.13 (+3.49%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
